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These studies suggest a complementary role for
TRPC4 in MFS-induced aortic pathology. Antagonism
of this novel target shows promise toward multi-drug
therapy for the treatment of aortic aneurysms in MFS.
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A Fbn1C1039G/+ heterozygous mouse, with a
mutation in fibrillin-1, was supplemented with
angiotensin II (4.5 mg/kg/day) to accelerate
aneurysmal formation. Mice analyzed were wild type
(wt) (saline +/- angiotensin II) and heterozygous
(saline +/- angiotensin II). Quantitative PCR and
western blotting was used to examine differential
expression of TRP channels across the various
cohorts. The TRPC4 antagonist, ML204
(10mg/kg/day), was given daily during two weeks of
angiotensin II infusion. Mice were echoed before and
after to assess aortic diameter.
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Marfan syndrome (MFS) is a genetic disease that
commonly presents with aortopathy. While promising
therapies have been studied, complete attenuation of
MFS-induced aortic aneurysms in the clinical arena
has been elusive. The presence of significant, not-yet
described MFS signaling pathways has been
suggested as a reason for the less than ideal clinical
response to single drug therapy. Transient receptor
potential (TRP) channels have emerged as likely
regulators of vascular smooth muscle cell (VSMC)
activity. In this regard, they are abundantly found in
VSMCs and are associated with increased matrix
metalloproteinase 9 activity. The current study seeks to
explore the role of TRP channels in MFS.
Quantitative PCR of the accelerated model revealed a near 10-fold
increase in TRPC4 transcription with respect to wt mice. ML204 and
losartan worked synergistically to ameliorate aortic dilation.
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This figure represents 
the percent change in 
aortic diameter over 
14 days following 
pharmacologic 
intervention of an 
accelerated MFS 
mouse with the use of 
Losartan (LT) and 
ML204 (ML). 
*indicates significance 
of P<.05 from all 
other groups.
This figure represents relative transcription of transient receptor potential 
channels with normalization to wt mice in triplicate.
Left: Protein expression of TRPC4 
normalized to wt mice from western 
blots of aortic tissue.
Above: Transillumination of a sample 
TRPC4 western blot.
Trp
c1
Trp
c3
Trp
c4
Trp
c6
Trp
v1
Trp
v2
Trp
v3
Trp
v4
Trp
m2
Trp
m3
Trp
m4
Trp
m7
0
4
8
12
16
Fo
ld
 C
ha
ng
e 
2-
Δ
Δ
ct
WT + Veh
MFS + Veh
MFS + Ang II
*
*P<.05
*
% Increase in Aortic Diameter over 14 days
W
T +
 Ve
h 
MF
S 
+ V
eh
W
T +
 A
NG
MF
S 
+ A
NG
MF
S+
AN
G+
LT
MF
S+
AN
G+
ML
MF
S+
AN
G+
LT
+M
L
100
120
140
160
